Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting Oct 24, 2022
Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease Oct 6, 2022
Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team Sep 29, 2022
Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting Sep 15, 2022
Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy Sep 8, 2022
Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference Sep 6, 2022
Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update Aug 12, 2022